natgillin/translations-raw huggingface dataset:
It is surprising that the dissolution rate of the pharmaceutical composition according to invention is not affected by the nature nor the amount of the inert core particle material. 
Iznenađuje da na brzinu otapanja farmaceutskog pripravka prema ovom izumu ne utječe priroda niti količina materijala čestica inertne jezgre.
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine. 
pri čemu se segment razmaka nalazi između 5’ segmenta „krila“ i 3’ segmenta„krila“; pri čemu svaki nukleozid iz svakog segmenta „krila“ obuhvaća cEt šećer; pri čemu svaka internukleozidna veza je fosforotioatna veza; i pri čemu svaki citozin je 5-metilcitozin.
A clinician skilled in the art can readily identify, by the use of clinical tests, physical examination and medical/family history, those subjects who are in need of such treatment. 
Klinički stručnjak će lako, kliničkim testovima, fizičkim ispitivanjem, te iz anamneze, identificirati subjekte kojima je potrebno takvo liječenje.
A method for measuring the temperature of a strand-like material to be heated to a target temperature, comprising the steps: 
Postupak mjerenja temperature predmeta u obliku strune koji treba zagrijati do ciljane temperature, naznačen time što obuhvaća korake:
On a molar equivalent basis, the compound of Example 1 is associated with less enteropathy than gemcitabine HCl while resulting in approximately twice the systemic. exposure to gemcitabine HCL. 
Na molarno ekvivalentnoj bazi, spoj iz Primjera 1 se povezuje s manjom enteropatijom nego gemcitabin-HCI, uz rezultirajuću približno dvostruko veliku sistemnu izloženost gemcitabinu-HCI.
A composition comprising a pharmaceutically effective amount of at least one peptide of claim 1 and a pharmaceutically acceptable carrier, excipient or diluent. 
Pripravak koja sadrži farmaceutski učinkovitu količinu peptida sukladno patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač, ekscipijens ili otapalo.
bisoprolol fumarate with a particle size controlled to 90% < 425 µm, as the second pharmaceutically active ingredient, blended with inert excipients and surrounding the tablet; 
tabletu koja sadrži aspirin kao prvi farmaceutski aktivni sastojak; i bisoprolol fumarat sa veličinom čestica kontroliranom do 90%
A method for preparing a compound for formula I, comprising contacting a compound of formula VI, with an acid under conditions suitable for forming an acid solvate of a compound of formula II: contacting the acid solvate of the compound of formula II with an amide under conditions suitable for forming an amide solvate of the compound of formula II; and contacting the amide solvate of the compound of formula II with an aqueous base comprising sodium ions under conditions suitable for forming the compound of formula I. 
H m OR OH OH II kontaktiranje kiselog solvata spoja s formulom II s amidom u pod uvjetima pogodnim za tvorbu amidnog solvata spoja s formulom II; 1 kontaktiranje amidnog solvata spoja s formulom II s vodenom bazom koja sadrži natrijeve ione pod uvjetima pogodnim za tvorbu spoja s formulom I.
a step of determining engine running times with the machine stopped and engine running times with the machine in motion; and 
- korak određivanja vremena rada motora sa zaustavljenim uređajem i vremena rada motora sa uređajem u kretanju;
A pharmaceutical tablet obtained by compression of a pharmaceutical tablet formulation of any of the claims 1 to 47. 
Farmaceutska tableta, naznačena time, da je dobivena komprimiranjem farmaceutske formulacije tablete u skladu s bilo kojim zahtjevom 1 do 13,
The crude harvest (CCM) of r-hIL6-IL6R chimera produced in CHO cells was loaded onto the column of MEP HYPERCEL® (Life technologies Cat. 
Sirovi materijal (CCM) himernog r-hIL6-IL6 proizveden u CHO stanicama nanešen je na kolonu MEp HyperCel (Life technologies Cat.
an amplifying circuit including a thermistor, said thermistor arranged to sense heat from said light emitting diode; and 
pojačivački sklop koji sadržava i termistor, navedeni termistor postavljen je tako da može bilježiti toplinu iz navedene LED diode; i
A third aspect of the disclosure is a method for producing a laminated product, for example a building panel, preferably a floor panel, wherein the method comprising the steps of: applying a powder based sub layer comprising wood fibers and a thermosetting resin on a wood fiber based core, e.g. 
Postupak za proizvodnju laminiranog proizvoda, na primjer građevinske ploče, poželjno podne ploče (P), naznačen time što postupak obuhvaća sljedeće korake: * nanošenje podsloja na bazi praha (12) koji sadrži drvena vlakna i termoreaktivnu smolu na jezgru na bazi drvenih vlakana (3), npr.
The use of claim 22 or 23, wherein the second agent is quinidine, and wherein the dosage amount of the compound of Formula I or pharmaceutically acceptable salt thereof is 10-60 mg, and the dosage amount of quinidine is 2.5-30 mg. 
Uporaba prema zahtjevu 20 ili 21, gdje je drugo sredstvo kinidin, 1 gdje je doza spoja Formule I ili njegove farmaceutski prihvatljive sol 10-60 mg, a doza kinidina je 2.5-30 mg. Pregstali Postotak
95.7 A process for preparing a purified conjugate in a solution, wherein the conjugate comprises a maytansinoid comprising a thiol group linked to an antibody, the process comprising the steps of: (a) contacting the maytansinoid with a bifunctional linker reagent to covalently attach the linker to the maytansinoid and thereby prepare an unpurified first mixture comprising the maytansinoid having linkers bound thereto, (b) conjugating an antibody to the maytansinoid having linkers bound thereto by reacting the unpurified first mixture with the antibody to prepare a second mixture, and (c) subjecting the second mixture to a tangential flow filtration, dialysis, gel filtration, adsorptive chromatography, selective precipitation or a combination thereof to thereby prepare the purified conjugate. 
Postupak za pripravu pročišćenog konjugata u otopini, naznačen time što konjugat sadrži majtanzinoid koji sadrži tiolnu skupinu vezanu na protutijelo, te postupak obuhvaća korake: (a) dovođenje u kontakt majtanzinoida s bifunkcionalnim veznim reagensom za kovalentno vezanje poveznice na majtanzinoid i na taj način pripravljanje nepročišćene prve smjese koja sadrži majtanzinoid s vezanim poveznicama, (b) konjugiranje protutijela na majtanzinoid s vezanim poveznicama reakcijom nepročišćene prve smjese s protutijelom da se dobije druga smjesa, te (c) podvrgavanje druge smjese tangencijalnoj protočnoj filtraciji, dijalizi, gel filtraciji, adsorpcijskoj kromatografiji, selektivnom taloženju ili njihovoj kombinaciji, te se na taj način pripravlja pročišćeni konjugat.
The board of claim 1, wherein the perlite filler has a mean particle diameter between 20 to 60 microns. 
Metoda u skladu sa patentnim zahtjevom 1, gdje je perlitni punilac obložen sa alkil alkoksi silanom.
The compound of any one of claims 1 to 7 or the pharmaceutical composition of any one of claims 8-11 for use as defined in any one of claims 12-14, wherein the compound or pharmaceutical composition is to be administered intravenously. 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 7, gdje se farmaceutska kompozicija treba administrirati intravenski u količini koja je u opsegu od 10 µg spoja sa formulom (1)/kg/minuti do 50 µg spoja sa formulom (1)/kg/minuti.
expressing a second fusion protein in the cell, the second fusion protein comprising a second zinc finger binding domain and a second cleavage half domain, wherein the second zinc finger binding domain binds to a second target site in or near the Zp15 locus in the genome of the plant cell, wherein the second target site is different from the first target site; and wherein binding of the first fusion protein to the first target site, and binding of the second fusion protein to the second target site, positions the cleavage half-domains such that the genome of the plant cell in or near the Zp15 locus is cleaved. 
(b) ekspresija drugog fuzijskog proteina u stanici, gdje drugi fuzijski protein obuhvaća drugu domenu vezanja cinkovih prstiju i drugu poludomenu cijepanja, dok druga domena vezanja cinkovih prstiju veže na drugo ciljano mjesto u samom Zp15-lokusu ili u njegovoj blizini u genomu biljne stanice, pri čemu je drugo ciljano mjesto različito od prvog ciljanog mjesta; te time, da vezanje prvog fuzijskog proteina na prvo ciljano mjesto, i vezanje drugog fuzijskog proteina na drugo ciljano mjesto, pozicionira poludomene cijepanja tako, da se genom biljne stanice cijepa u samom Zp15-lokusu ili u njegovoj blizini.
distilling said crude product to produce an overhead stream and a bottom stream, the overhead stream comprising 1,1,1,3-tetrachloropropane and unreacted carbon tetrachloride, and the bottom stream comprising 1,1,1,3-tetrachloropropane; 
destilaciju tog sirovog proizvoda radi dobivanja gornjeg i donjeg protoka, gornji protok sadrži 1,1,1,3-tetrakloropropan i neizreagirani ugljik tetraklorid, i donji protok sadrži 1,1,1,3-tetrakloropropan;
The kit of claim 1, wherein the medical procedure is selected from the group consisting of colonoscopy, intestinal surgery, virtual colography, and barium studies. 
Komplet iz patentnog zahtjeva 1, pri tome se medicinski postupak izabire iz skupine koja sadrži kolonoskopiju, intestinalni zahvat, virtualnu kolografiju, i proučavanja barija.
The solid pharmaceutical composition according to any one of claims 1 to 6, which is designed for release of the lipophilic drug either in the gut or in the intestine, preferably a composition that forms colloidal nanodispersion upon contact with biological fluids with pH 6-8 that corresponds to the pH of intestinal fluids. 
Kruti farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 6, koji je namijenjen za oslobađanje lipofilnog lijeka bilo u utrobi ili crijevima, poželjno pripravak koji tvori koloidnu nanodisperziju u kontaktu s biološkim tekućinama s pH 6-8 koji odgovara pH crijevnih tekućina. HR P20191104T1 11.
A compound of formula (X): wherein R' is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R' is trimethylsilyl and R is tert-butoxycarbonyl; or R and R' taken together with the nitrogen atom they are linked to form a phthalimido group; and wherein the line means that the double bond of the beta-enaminoketone group can be in cis or trans configuration. 
IX) u kojoj je X odabran od sljedećih: Cl, Br ili I te naznačen time da R' jest vodik i R je odabran od sljedećih: benzil, acetil, benzoil, trifluormetanesulfonil, benzenesulfonil, p-toluenesulfonil, metoksikarbonil, etoksikarbonil, tert-butoksikarbonil, aliloksikarbonil i benziloksikarbonil koji može biti supstituiran na aromatskom prstenu s do trima supstituentima odabrani od sljedećih: halogen, cijano i trifluorometil; ili R* jest trimetilsilil i R jest tert-butoksikarbonil; ili R i R' uzeti zajedno s dušikovim atomom za koji su vezani tvore ftalimido-skupinu.
A compound of claim 1 of the formula or a pharmaceutically acceptable salt, stereoisomer and/or solvate thereof. 
C C l =N ili njena farmaceutski prihvatljiva sol, stereoizomer i/ili solvat.
The floating lake system of claim 1, wherein the bottom material is a flexible material selected from the group consisting of rubbers, plastics, teflon, low density polyethylene, high density polyethylene, polypropylene, nylon, polystyrene, polycarbonate, Polyethylene Terephthalate, fibers, fiberboard, woods, polyamides, PVC membranes, fabrics, composite fabrics, geomembranes, acrylics, and combinations thereof. 
Sustav plutajućeg jezera (1) prema zahtjevu 14, naznačen time što je materijal dna (2) savitljivi materijal odabran iz skupine koja se sastoji od gume, plastike, teflona, polietilena niske gustoće, polietilena visoke gustoće, polipropilena, najlona, polistirena, polikarbonata, polietilen tereftalata, vlakana, ploča vlaknatica, drva, poliamida, PVC membrana, tkanina, kompozitnih materijala, geomembrana, akrila i njihovih kombinacija.
Use of a compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient for the production of a pharmaceutical agents for treating a disease causing by an undesirable cell proliferation. Use of claim 18, wherein the disease causing by an undesirable cell proliferation is rheumatism. 
Upotreba spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj formule [I] aktivni sastojak u proizvodnji farmaceutskog sredstva za liječenje bolesti koju uzrokuje nepoželjna stanična proliferacija.
The method according to claim 1, wherein said nitrate and/or nitrite is administered together with polyphenols. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu se navedeni nitrat i/ili nitrit daje zajedno s polifenolima.
A method of claim 6 or 7 wherein the protein of interest is recombinantly-produced rFVI l I. 
Metoda iz patentnog zahtjeva 6 ili 7 pri čemu je protein od interesa rekombinantno proizvedeni rFVIII.
Methods of Making the Vaccine Compositions of the Invention 
Broj objave europskog patenta:
An electrically heated smoking system according to claim 1, 2 or 3, wherein the one or more electrically conductive tracks are on the outside of the tube of electrically insulating substrate. 
Električno grijani sustav za pušenje u skladu s patentnim zahtjevom 1, 2 1li 3, naznačen time što se jedna ili više električno vodljivih tračnica (203) nalazi s vanjske strane cijevi od električno izolirajuće podloge (201).
Process for the preparation of a compound of the formula (I): 
Postupak proizvodnje spoja formule (I):
Foreign impurities, for example those deriving from environmental pollutants, such as heavy metals, usually measured in concentrations of “parts per million” (ppm), will always be conform to the analytic specifications, in particular the ones of E.P. 
Strana onečišćenja, na primjer ona koja nastaju od zagađivača iz okoliša, kao što su teški metali, obično se mjere u koncentracijama "dijelova na milijun" (ppm), će uvijek biti u skladu s analitičkim specifikacijama, naročito onima iz E.P.
According to another aspect of the present invention, said organic material may comprise a waste, such as house hold waste, municipal solid waste, paper waste, auto shredder waste, plastics, polymers, rubbers, scrap tires, cable wastes, CCA treated wood, halogenated organic compounds, PCB bearing transformer oils, electrolytic capacitors, halones, medical waste, risk material from meat processing, meat and bone meal, liquid streams, such as process or waste water streams containing dissolved and/or suspended organic material. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu navedeni organski materijal obuhvaća otpad, kao što je otpad iz kućanstva, komunalni kruti otpad, otpadni papir, automatski usitnjeni otpad, plastiku, polimere, gume, otpadne gume vozila, otpadne kablove, CCA tretirano drvo, halogenirane organske tvari, transformirana ulja koja nose PCB, elektrolitske kapacitatore, halone, medicinski otpad, rizični materijal 12 obrade mesa, obroke mesa i kostiju, tekuće protoke, kao što su protoci obradne ili otpadne vode koji sadrže otopljeni i/ili suspendirani organski materijal.
applying a solution comprising poly (ethylene glycol) and sorbitol to a chromatography material to which an antibody had been adsorbed, whereby the four chain full length antibody in monomeric form remains adsorbed to an ion exchange chromatography material, and recovering the four chain full length CrossMab antibody in monomeric form from the ion exchange chromatography material by applying a solution comprising poly (ethylene glycol) and sorbitol, whereby the poly (ethylene glycol) has a concentration of 10 % by weight and the sorbitol has a concentration of from 5 % to 20 % by weight, and thereby producing the antibody. 
- nanošenje otopine koja sadrži poli (etilenglikol) i sorbitol na kromatografski materijal na koji je protutijelo bilo adsorbirano, pri čemu protutijelo četverostrukog lanca pune duljine u monomernom obliku ostaje adsorbirano na kromatografskom materijalu ionske izmjene, i - < dobivanje CrossMab-protutijela u monomernom obliku četverostrukog lanca pune duljine iz kromatografskog materijala ionske izmjene primjenom otopine koja sadrži poli(etilenglikol) 1 sorbitol, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih %, a sorbitol ima koncentraciju od 5 masenih % do 20 masenih %, te time proizvodnja protutijela.
The extruded polymer blend of claim 1, wherein the one or more polyethylene terephthalate homopolymers or copolymers comprise one or more virgin polymers having an intrinsic viscosity ranging from 0.72 to 0.88 dL/g obtained through a melt phase polymerization. 
Smjesa polimera u skladu s patentnim zahtjevima 1-10, naznačena time što jedan ili više homopolimera ili kopolimera polietilen-tereftalata imaju unutarnju viskoznost izmjerenu na 25 *C u 60:40 tež./tež. fenol/tetrakloretan od najmanje 0,72 dl/g, dobivenih polimerizacijom u rastaljenoj fazi.
preparing a compound of formula 16 via arylation of a compound of formula 17; 
pripravu spoja s formulom 16 putem arilacije spoja s formulom 17;
The process of claim 3, wherein said lower alkyl carbonyl compound is selected from the group consisting of acetaldehyde, acetone, glyoxylic acid, and gyloxylate. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni niži alkilkarbonilni spoj se bira iz skupine koju čine acetaldehid, aceton, glioksilna kiselina i giloksilat.
The therapeutic agent for pain according to claim 3, wherein Ring Ac is phenyl substituted with halogen. 
Spoj ili njegova sol za uporabu prema zahtjeva 2, naznačen/a time, da Prsten A" je fenil koji je supstituiran s halogenom.
The method of claims 1 to 6, wherein the non-polar organic solvent is a straight-chain or branch-chain (C4-C10)aliphatic hydrocarbon, a (C4-C10)cycloaliphatic hydrocarbon, or any mixture thereof, wherein the straight-chain or branch-chain hydrocarbon is preferably pentane, hexane, heptane, isooctane, or any mixture thereof and is more preferably n-heptane. 
Postupak prema zahtjevima 1 do 6, naznačen time da je nepolamo organsko otapalo (C;-C,o)alifatski ugljikovodik sa ravnim-lancem ili razgranatim-lancem, (Cy-Cjo)cikloalifatski ugljikovodik, ili bilo koja njihova mješavina, pri čemu je poželjno da je ugljikovodik sa ravnim-lancem ili razgranatim-lancem pentan, heksan, heptan, izooktan, ili bilo koja njihova mješavina, i još poželjnije je n-heptan,
Floor panel according to any of the preceding claims, characterized in that the insert consists of a strip of synthetic material. 
Podni panel prema patentnom zahtjevu 9 ili 10, naznačen time što se zasebni umetak sastoji od okretnog elementa za blokiranje.
A product comprising (a) a B2 agonist as defined in any one of claims 1 and 3 to 7 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease as defined in claim 11 or 12. 
Proizvedeni lijek, naznačen time, da sadrži (a) inhibitor PDE4 kako se definira u bilo kojem od patentnih zahtjeva 113 do 6 i (b) antagonist muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2, u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u liječenju bolesnika koji boluje od ili je osjetljiv na bolest dišnih putova koja reagira na M3 antagonizam.
a heavy chain comprising an amino acid sequence provided as SEQ ID NO. 16, SEQ ID NO. 24, or a deamidated and/or oxidized variant thereof. 
jaki lanac koji sadrži aminokiselinsku sekvencu danu kao SEQ ID NO:16, SEQ ID NO:24 ili njezinu deamidiranu i/ili oksidiziranu varijantu.
Hence, the weight 452, 552, 652 may be moved so as to counteract the tilting momentum exerted by the load in a direction being transverse to the centre axis CA of the transloader 200, 300, 400, 600 . 
Plovilo (200, 300, 400, 600) sukladno zahtjevu 6, pri čemu je električni motor (568a, b) organiziran da djeuje izravno na opremu (564) na način da se uteg (452, 552, 652) pomiče.
R2i' is one of C1-10alkyl, -CH2aryl, -S(O)2aryl, and -S(O)2C1-6alkyl, where said C1-10alkyl moiety is linear or branched, and said C1-10alkyl and said aryl moieties are optionally substituted with at least one substituent in the group of halo and C1-6alkyl; and R2i is one of H and R2i'. 
R»' je jedan od C,.oalkila, -CHoarila, -S(O)arila, i -S(O),C,.salkila, gdje je navedeni C,.qoalkil ostatak linearan ili razgranat, i navedeni Crggalkil 1 navedeni aril ostaci su opcionalno supstituirani s najmanje jednim . supstituentom iz grupe halo i C,.salkil; i
One or several binders according to the invention are preferably selected from the group consisting of polyvidone (used synonymously for povidone), methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxymethylcellulose, starch, gelatin, and the like. 
Čvrsta formulacija prema patentnom zahtjevu 2 ili 3, naznačena time, da je vezivo odabrano iz skupine koja se sastoji od polividona/povidona, metilceluloze, hidroksipropilmetilceluloze (HPMC), hidroksimetilceluloze, škroba i želatine.
converting, in the DNA, cytosine unmethylated in the 5-position to uracil or another base that does not hybridize to guanine; 
(a) pretvaranje, koje se vrši u DNA, citozina nemetiliranog na 5. mjestu u uracil ili neku drugu bazu koja ne hibridizira u guanin;
A UV radiation (UVR) response indicator which comprises a first UVB and/or UVA radiation sensitive material which has been modified so as to display an altered characteristic in a delayed manner in response to UVB and/or UVA radiation exposure, wherein the first UVB and/or UVA radiation sensitive material comprises a UVB and/or UVA radiation-driven acid release agent and a pH indicator which displays altered colour between deprotonated and acid forms, wherein the UVB and/or UVA radiation-driven acid release agent includes a dye comprising an iodonium or sulphonium salt, and wherein the first UVB and/or UVA radiation sensitive material further comprises a proton-scavenging agent so as to delay protonation of the pH indicator by the UVB and/or UVA radiation-driven acid release agent, wherein the proton-scavenging agent is a base. 
Indikator odgovora na UV zračenje (UVR) koji sadrži prvi materijal koji je osjetljiv na UVB i/ili UVA zračenje koji je modificiran tako da na odgođeni način prikazuje promijenjenu karakteristiku kao odgovor na izlaganje UVB i/ili UVA zračenju, naznačen time da prvi materijal koji je osjetljiv na UVB i/ili UVA zračenje sadrži sredstvo za otpuštanje kiseline pokretano UVB i/ili UVA zračenjem i pH indikator koji prikazuje promijenjenu boju između deprotoniranih i kiselih oblika, pri čemu sredstvo za otpuštanje kiseline pokretano UVB i/ili UVA zračenjem sadrži boju koja sadrži jodonijevu ili sulfonijevu sol, te time da prvi materijal koji je osjetljiv na UVB 1/ili UVA zračenje nadalje sadrži sredstvo koje veže protone tako da se odgodi protonacija pH indikatora sa sredstvom za otpuštanje kiseline pokretanim UVB i/ili UVA zračenjem, pri čemu sredstvo koje veže protone je baza.
The bispecific antibody or antibody fragment according to any one of the claims 1 to 9 for suppressing a TH-2 mediated response in a mammal. The bispecific antibody or antibody fragment thereof according to one of the claims 1 to 8 comprising a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba bispecifičnog protutijela ili fragmenta protutijela prema bilo kojem od zahtjeva 1 do 7 naznačena time da je za istraživanje ili in vitro dijagnostičke primjene, pri čemu navedeno bispecifično protutijelo ili njegov fragment protutijela sadrži oznaku kao što je radioobilježivač, fluorofor, kromofor, sredstvo za snimanje ili metalni ion.